Sacha Gnjatic, PhD
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
- ASSOCIATE PROFESSOR | Oncological Sciences
- ASSOCIATE PROFESSOR | Pathology, Molecular and Cell Based Medicine
Research Topics:Anti-Tumor Therapy, Antigen Presentation, B Cells, Cancer, Cellular Immunity, Dendritic Cells, Immunological Tolerance, Immunology, Immunosuppression, Lung, Microarray, Proteomics, T Cells, Tolerance, Translation, Vaccine Development
Dr. Sacha Gnjatic received his PhD in Immunology
from the University of Paris VII after completing a fellowship at the Institut
Cochin in Paris. Following a post-doctoral fellowship in Lloyd J. Old’s
laboratory at Memorial Sloan-Kettering (MSKCC) in New York, Dr. Gnjatic
was appointed to the Ludwig Institute for Cancer
MSKCC, where he eventually became Associate Member, and was named Director of
Immunological Monitoring at the Ludwig Center for Immunotherapy.
In 2013, Dr. Gnjatic moved to Icahn School of Medicine at Mount Sinai, New York, where he was appointed as Associate Professor of Medicine at the Tisch Cancer Institute and Immunology Institute. In addition, he serves as Associate Director of the Human Immune Monitoring Center at Mount Sinai.
Dr. Gnjatic focuses on human immune responses to cancer in an antigen-specific manner, to define new targets for the development of cancer immunotherapies, ask how these immunotherapies work and why they may fail. Areas of research include: Characterization of serological and cellular immune responses against tumor antigens such as MAGE-A3 or NY-ESO-1, spontaneously occurring or induced by cancer immunotherapy, using state-of-the-art T cell methods and large-scale seromic profiling; Mechanisms of antigen presentation to T cells, to evaluate viral, bacterial, and parasitic vectors, and cross-presentation of antigen to HLA; Impact of immunoregulation on tumor antigen-specific responses, from co-inhibitory molecules expressed on T cells at the tumor site to the effect of regulatory T cells and immune checkpoint blockade on anti-tumor effectors, with a recent emphasis on the role of immunosuppressive mechanisms in the tumor microenvironment.
Dr. Gnjatic’s research has established the immunological bases for evaluating human cancer vaccines in over 40 clinical trials. His work has resulted in more than 120 publications in high-impact peer-reviewed journals and nearly 10 patents.
Multi-Disciplinary Training AreaImmunology [IMM]
BSc3, University College London
MSc, Institut Pasteur
Undergraduate, Ecole Normale Supérieure
PhD, University Paris VII
Memorial Sloan-Kettering - Ludwig Institute
Characterization of serological and cellular immune responses against tumor antigens:
Characterization of serological and cellular immune responses against tumor antigens such as p53, MAGE-A3, and NY-ESO-1, for their capacity to induce immune responses both spontaneously and in the setting of cancer immunotherapy. Pioneering large-scale seromic profiling to find biomarkers and new targets of tumor immunity.
Mechanisms of antigen presentation to T cells:
Mechanisms of antigen presentation to T cells, including defining epitopes, evaluating viral, bacterial, and parasitic vectors, cross-presentation of antigen to HLA class I, and endogenous antigen presentation to HLA class II.
Impact of immunoregulation on tumor antigen-specific responses:
Impact of immunoregulation on tumor antigen-specific responses, from co-inhibitory molecules expressed on T cells at the tumor site to the effect of regulatory T cells on anti-tumor effectors.